JGC
VRDN icon

J. Goldman & Co’s Viridian Therapeutics VRDN Stock Holding History

J. Goldman & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,598
Closed -$251K – 944
2026
Q1 		$305K Sell
15,598
-52,456
-77% -$1.56M 0.01% 564
2025
Q4 		$2.12M Sell
68,054
-1,972
-3% -$54.1K 0.06% 305
2025
Q3 		$1.51M Sell
70,026
-30,751
-31% -$555K 0.04% 300
2025
Q2 		$1.41M Sell
100,777
-17,817
-15% -$242K 0.03% 316
2025
Q1 		$1.6M Sell
118,594
-60,902
-34% -$1.04M 0.04% 323
2024
Q4 		$3.44M Buy
+179,496
New +$3.9M 0.09% 224
2024
Q3 		– Sell
-74,985
Closed -$976K – 633
2024
Q2 		$976K Buy
74,985
+30,721
+69% +$425K 0.03% 307
2024
Q1 		$775K Buy
+44,264
New +$858K 0.03% 291

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

J. Goldman & Co's VRDN Position: Q2 2026 in Review

J. Goldman & Co sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 15,598 shares — an estimated $251K sold.

J. Goldman & Co first reported a position in VRDN in Q1 2024 and held it in 8 quarters. The position peaked at $3.44M in Q4 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • J. Goldman & Co reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 15,598 Viridian Therapeutics shares in Q2 2026, an estimated $251K.
  • J. Goldman & Co first reported a position in Viridian Therapeutics in Q1 2024 and held it in 8 quarters.
  • J. Goldman & Co's Viridian Therapeutics position peaked at $3.44M in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.